Role of Litigation in Defining Drug Risks_JAMA / BMJ
Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known.
Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known.
Readers of the New England Journal of Medicine should be forewarned: The information in the pages of the NEJM is tainted by industry influence, its professional and scientific integrity are tainted.
The question is: will Eli Lilly succeed, once again, to divert public attention from the revelations contained in its internal documents about the company's illegal marketing practices and its failure to warn about lethal risks posed by its product?
NY Times reports: In March 2002, Lilly rejected plans to give psychiatrists guidance about how
to treat diabetes, "worrying that doing so would tarnish Zyprexa's reputation."
An eye opening article by Jeanne Lenzer, “NIH Secrets,” in The New Republic (below), should make the new Congress sit up and take notice!
FDA's slip-shod approval of defective, harmful drugs, accompanied by rubber stampped endorsements by compromised FDA advisory committees may be reaching a boiling point.
The ethics of this radical drug experiment is being challenged by Dr. Jerald Block, a forthright psychiatrist and experienced system's analyst. His critical appraisal, published in the Bioethics Forum, Hastings Center Report.
The Whistleblower: Confessions of a Healthcare Hitman by Dr. Peter Rost, published by Soft Skull Press.
Two surveys confirm medical researchers' resistance to complying with conflict of interest disclosure requirements.
Medical researchers who commit fraud and research misconduct are caught only when a person of conscience steps up to the plate and blows the whistle. There are no systemic, independent checks and balances to prevent research fraud or abuse of patients.
Prescriptions And Profit_CBS News 60 Minutes Tue, 16 Mar 2004 “Americans pay far more for their prescription drugs than citizens of any place on Earth.” That’s because “The United States is the only industrialized country without some form of control on the prices of drugs.” No wonder the U.S. accounts…
A Disease for Every Pill – FDA Hearing Drug Advertising Wed, 5 Oct 2005 The FDA has called for a public hearing to address direct to consumer drug advertising. Hearing Date: November 1 and 2, 2005 Hearing Name: Direct-To-Consumer Promotion Location: National Transportation Safety Board Boardroom and Conference Center 429…